Kamada Ltd KMDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
-
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
-
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
-
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
-
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
-
Kamada Announces Planned Transition of Chief Financial Officer
-
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 57.71M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 19.51
- Price/Sales
- 2.33
- Dividend Yield (Trailing)
- 2.11%
- Dividend Yield (Forward)
- 2.11%
- Dividend Payment Schedule
- Apr, Sep
- Total Yield
- 2.11%
Company Profile
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 462
- Website
- https://www.kamada.com
Valuation
|
Metric
|
KMDA
|
|---|---|
Price/Earnings (Normalized) | 19.51 |
Price/Book Value | 1.80 |
Price/Sales | 2.33 |
Price/Cash Flow | 9.69 |
Price/Earnings
KMDA
Financial Strength
|
Metric
|
KMDA
|
|---|---|
Quick Ratio | 2.29 |
Current Ratio | 4.06 |
Interest Coverage | 24.95 |
Quick Ratio
KMDA
Profitability
|
Metric
|
KMDA
|
|---|---|
Return on Assets (Normalized) | 6.83% |
Return on Equity (Normalized) | 9.98% |
Return on Invested Capital (Normalized) | 9.12% |
Return on Assets
KMDA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|wk%zzSZ# | LOCK|^^?! | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|<cx>Q%n | LOCK|t^Gz | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|wRhbx@ | LOCK|V@ | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|$CZNBv$H | LOCK|>y | $33B | |||
| Viatris Inc
VTRS
| LOCK|>C&@r&< | LOCK|M<! | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|Sh | LOCK|@! | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|R>MxJQ | LOCK|?nv | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|Bd>$@! | LOCK|Fbk | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|TX&?R! | LOCK|Njc?& | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|$Cms<w! | LOCK|K&? | $2B |
United States